Title Statements
- Full title :Anticancer drug development / edited by Bruce C. Baguley, David J. Kerr.
Edition Statements
- Publication Date:c2002.
Publication Statements
- Publisher(s):Academic Press
- Place of Publication:San Diego
- Language:eng
- Publication Date:c2002.
The Physical Object
- Description:xiii, 397 p. : : ill. (some col.) ; : 29 cm.
Edition Identifiers
- ISBN:0120726513, 9780120726516
- oclc:on1166801386
- LC Classification:RS431.A64
- Dewey Decimal:616.99/4061
Table of Contents
A brief history of cancer chemotherapy -- Novel targets in the cell cycle and cell cycle checkpoints -- Growth factor and signal transduction targets for cancer therapy -- Cell death pathways as targets for anticancer drugs -- Drug resistance pathways as targets -- Role of matrix metalloproteinases and plasminogen activators in cancer invasion and metastasis: therapeutic strategies -- Tumor vasculature as a target -- Gene-directed enzyme prodrug therapy -- Tumor antigens as targets for anticancer drug development -- Structure-based drug design and its contributions to cancer chemotherapy -- The contribution of synthetic organic chemistry to anticancer drug development -- Biosynthetic products for anticancer drug design and treatment: the bryostatins -- DNA-encoded peptide libraries and drug discovery -- Mechanism-based high-throughput screening for novel anticancer drug discovery -- Tumor cell cultures in drug development -- Screening using animal systems -- Relevance of preclinical pharmacology and toxicology to Phase I trial extrapolation techniques: relevance of animal toxicity -- Clinical trial design: incorporation of pharmacokinetic, pharmacodynamic, and pharmacogenetic prin…
Read More ↓Subjects
Writers
No reviews yet. Be the first to rate this work.
Rate & Review